ANDA 205049, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 205049 (Norethindrone Acetate And Ethinyl Estradiol And Ethinyl Estradiol And Ferrous Fumarate), held by Xiromed, was first approved by FDA on May 31, 2016, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol And Ethinyl Estradiol And Ferrous Fumarate0.01MG,0.01MG;1MG,N/A · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Oct 14, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 13, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 13, 2026 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 20, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 20, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| May 31, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters